These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38990319)

  • 1. Dolutegravir-induced neural tube defects in mice are folate responsive: Erratum.
    AIDS; 2024 Aug; 38(10):1607. PubMed ID: 38990319
    [No Abstract]   [Full Text] [Related]  

  • 2. Lessons from dolutegravir and neural tube defects.
    Abrams E; Myer L
    Lancet HIV; 2021 Jan; 8(1):e3-e4. PubMed ID: 33387476
    [No Abstract]   [Full Text] [Related]  

  • 3. Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception.
    Zash R; Makhema J; Shapiro RL
    N Engl J Med; 2018 Sep; 379(10):979-981. PubMed ID: 30037297
    [No Abstract]   [Full Text] [Related]  

  • 4. Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana.
    Zash R; Holmes L; Diseko M; Jacobson DL; Brummel S; Mayondi G; Isaacson A; Davey S; Mabuta J; Mmalane M; Gaolathe T; Essex M; Lockman S; Makhema J; Shapiro RL
    N Engl J Med; 2019 Aug; 381(9):827-840. PubMed ID: 31329379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dolutegravir-induced neural tube defects in mice are folate responsive.
    Tukeman GL; Wei H; Lin YL; Wlodarczyk BJ; Finnell RH; Cabrera RM
    AIDS; 2024 Mar; 38(4):439-446. PubMed ID: 37382903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels.
    Mohan H; Lenis MG; Laurette EY; Tejada O; Sanghvi T; Leung KY; Cahill LS; Sled JG; Delgado-Olguín P; Greene NDE; Copp AJ; Serghides L
    EBioMedicine; 2021 Jan; 63():103167. PubMed ID: 33341441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study.
    Pereira GFM; Kim A; Jalil EM; Fernandes Fonseca F; Shepherd BE; Veloso VG; Rick F; Ribeiro R; Pimenta MC; Beber A; Corrêa RG; Lima R; Maruri F; McGowan CC; Schwartz Benzaken A; Grinsztejn B; Castilho JL;
    Lancet HIV; 2021 Jan; 8(1):e33-e41. PubMed ID: 33387477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dolutegravir-induced severe sideroblastic anemia.
    Lemoine S; Bobo M; Hocqueloux L; Legac E; Prazuck T
    AIDS; 2024 Jun; 38(7):1095-1097. PubMed ID: 38691054
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical Extrapolation of the Effects of Dolutegravir and Other HIV Integrase Inhibitors on Folate Transport Pathways.
    Zamek-Gliszczynski MJ; Zhang X; Mudunuru J; Du Y; Chen JL; Taskar KS; Huang J; Huang Y; Romach EH
    Drug Metab Dispos; 2019 Aug; 47(8):890-898. PubMed ID: 31167838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda.
    Alhassan Y; Twimukye A; Malaba T; Orrell C; Myer L; Waitt C; Lamorde M; Kambugu A; Reynolds H; Khoo S; Taegtmeyer M
    BMC Public Health; 2020 Dec; 20(1):1883. PubMed ID: 33287795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rollout of dolutegravir-based antiretroviral therapy in sub-Saharan Africa and its public health implications.
    Wilson HI; Mapesi H
    Pan Afr Med J; 2020; 37():243. PubMed ID: 33552361
    [No Abstract]   [Full Text] [Related]  

  • 12. Dolutegravir-induced hyperglycaemia in a patient living with HIV.
    McLaughlin M; Walsh S; Galvin S
    J Antimicrob Chemother; 2018 Jan; 73(1):258-260. PubMed ID: 29077869
    [No Abstract]   [Full Text] [Related]  

  • 13. Is There a Safety Signal for Dolutegravir and Integrase Inhibitors During Pregnancy?
    Chouchana L; Beeker N; Treluyer JM
    J Acquir Immune Defic Syndr; 2019 Aug; 81(4):481-486. PubMed ID: 31021990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disparities in Dolutegravir Uptake Affecting Females of Reproductive Age With HIV in Low- and Middle-Income Countries After Initial Concerns About Teratogenicity : An Observational Study.
    Romo ML; Patel RC; Edwards JK; Humphrey JM; Musick BS; Bernard C; Maina MW; Brazier E; Castelnuovo B; Penner J; Wyka K; Cardoso SW; Ly PS; Kunzekwenyika C; Cortés CP; Panczak R; Kelvin EA; Wools-Kaloustian KK; Nash D;
    Ann Intern Med; 2022 Jan; 175(1):84-94. PubMed ID: 34843382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dolutegravir and neural tube defects: a new insight.
    Chouchana L; Pariente A; Pannier E; Tsatsaris V; Treluyer JM
    Lancet Infect Dis; 2020 Apr; 20(4):405-406. PubMed ID: 32222203
    [No Abstract]   [Full Text] [Related]  

  • 16. Dolutegravir for pregnant women living with HIV.
    Zipursky J; Loutfy M
    CMAJ; 2020 Mar; 192(9):E217-E218. PubMed ID: 32122978
    [No Abstract]   [Full Text] [Related]  

  • 17. Periconception dolutegravir use in women living with HIV and missed opportunities in maternal and child health.
    Myer L
    Lancet Child Adolesc Health; 2019 Oct; 3(10):669-671. PubMed ID: 31375312
    [No Abstract]   [Full Text] [Related]  

  • 18. Dolutegravir in late pregnancy: where to from here?
    Kufa T
    Lancet HIV; 2022 Aug; 9(8):e522-e523. PubMed ID: 35905749
    [No Abstract]   [Full Text] [Related]  

  • 19. Changes to dolutegravir policy in several African countries.
    Nakkazi E
    Lancet; 2018 Jul; 392(10143):199. PubMed ID: 30043745
    [No Abstract]   [Full Text] [Related]  

  • 20. Dolutegravir Use at Conception - Additional Surveillance Data from Botswana.
    Raesima MM; Ogbuabo CM; Thomas V; Forhan SE; Gokatweng G; Dintwa E; Petlo C; Motswere-Chirwa C; Rabold EM; Tinker SC; Odunsi S; Malima S; Mmunyane O; Modise T; Kefitlhile K; Dare K; Letebele M; Roland ME; Moore CA; Modi S; Williamson DM
    N Engl J Med; 2019 Aug; 381(9):885-887. PubMed ID: 31329378
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.